BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Rie Maurer

eRA COMMONS USER NAME (credential, e.g., agency login): RMAURER

POSITION TITLE: Biostatistian

EDUCATION/TRAINING *(Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.*)

INSTITUTION AND LOCATION	DEGREE *(if applicable)*	Completion Date MM/YYYY	FIELD OF STUDY
Boston University, Boston, MA	B.A.	1994	Psychology
Association of Clinical Research Professionals, Boston, MA	Certification	1996	Certified CRC
Boston University, Boston, MA	M.A.	1999	Biostatistics

A. Personal Statement

My contributions to research have been ongoing since 1994, when I started working as a clinical research coordinator for the Gastroenterology group at Faulkner hospital. Currently I am a biostatistician in the BWH Center for Clinical Investigation, the BWH Division of Women's Health, and the Harvard Catalyst Biostatistics Core. I collaborate with investigators on protocol design, sample size calculation, and analysis planning. I also collaborate with investigators on grant applications and IRB submissions at both the clinical and bench research levels; several grant applications were successful in obtaining funding. I perform statistical analyses for abstract or manuscript submissions, including categorical data analysis, non-parametric methods, survival analysis, logistic/linear regressions, repeated measures, random effects models, and meta-analyses.

B. Positions and Honors

Positions and Employment

1994–2003 Research Coordinator, Gastroenterology, Faulkner Hospital, Boston, MA
1999–2003 Biostatistician, Gastroenterology, Faulkner Hospital, Boston, MA
2003–2009 Biostatistician, Medicine (Gastroenterology), Brigham and Women's Hospital, Boston, MA
2004– Biostatistician, Center for Clinical Investigation, Brigham and Women's Hospital, Boston, MA
2009– Biostatistician, Medicine (Women's Health), Brigham and Women's Hospital, Boston, MA

Other Experience

1999 Contract Statistician, Beth Israel Deaconess Medical Center
2002 Contract Statistician, Lahey Clinic Medical Center
2004 Contract Statistician, Beth Israel Deaconess Medical Center

Professional Memberships

1996–2008 Member, Association of Clinical Research Professionals
2002–2008 Member, American Association for the Study of Liver Disease
2003– Member, American Statistical Association

C. Contribution to Science

1. Serving as a consulting biostatistician for the Harvard Catalyst, I collaborated with investigators or medical students in a variety of area of medicine and performed statistical analysis.
    a. Gliklich J, Maurer R, Bergmark RW. (in press) Patterns of texting and driving in a US national survey of millennial parents vs older parents. JAMA Pediatr. 2019 doi: 10.1001/jamapediatrics.2019.0830.
    b. Angell TE, Maurer R, Wang Z, Kim MI, Alexander CA, Barletta JA, Benson CB, Cibas ES, Cho NL, Doherty GM, Doubilet PM, Frates MC, Gawande AA, Krane JF, Marqusee E, Moore FD, Nehs MA, Larsen PR, Alexander EK. A Cohort Analysis of Clinical and Ultrasound Variables Predicting Cancer Risk in 20,001 Consecutive Thyroid Nodules. J Clin Endocrinol Metab. 2019 Jul 16. pii: jc.2019-00664.
    c. Tsao L, Slater SE, Doyle KP, Cuong DD, Khanh QT, Maurer R, Minh Thy DN, Quoc Thinh DH, Tuan TD, Van Dung D, Khue LN, Krakauer EL. Palliative Care-Related Knowledge, Attitude, and Self-Assessment Among Physicians in Vietnam. J Pain Symptom Manage. 2019 Aug 16. pii:S0885-3924(19)30438-5.

2. In addition to the contributions described above, I specialized in biostatistical analysis of pulmonary research. I served as a biostatistician to in all of these studies
    a. Rosas IO, Goldberg HJ, Collard HR, El-Chemaly S, Flaherty K, Hunninghake GM, Lasky JA, Lederer DJ, Machado R, Martinez FJ, Maurer R, Teller D, Noth I, Peters E, Raghu G, Garcia JGN, Choi AMK. A Phase II Clinical Trial of Low-Dose Inhaled Carbon Monoxide in Idiopathic Pulmonary Fibrosis. Chest. 2018;153(1):94-104
    b. Fredenburgh LE, Parrella MA,Barragan-Bradford D, Hess DR, Peters E, Welty-Wolf KE, Kraft BD, Harris RS, Maurer R, Nakahira K, Oromendia C, Davis JD, Higuera A, Schiffer KT, Englert JA, Dieffenbach, PB, Berlin DA, Lagambina, S, Bouthot M, Sullivan AL, Nuccio PF, Kone MT, Malik MJ, Porras MAP, Finkelsztein E, Winkler T, Hurwitz S, Serchan CN, Piantadosi CA, Baron RM, Thompson BT, Choi AM. A phase I trial of low-dose carbon monoxide in sepsis-induced ARDS. JCI Insight 2018 Dec 6; 3(23).
    c. El-Chemaly S, Taveira-DaSilva A, Bagwe S, Klonowska K, Machado T, Lamattina AM, Goldberg HJ, Jones AM, Julien-Williams P, Maurer R, Rosas IO, Henske EP, Moss J, Kwiatkowski DJ. Celecoxib in LAM: Results of a Phase I Clinical Trial. Eur Respir J 2020 Feb 20. pii: 1902370. doi: 10.1183/13993003.02370-2019.

3. My recent publications are in an area of women's health area, family planning field. These publications evaluated different methods of surgical or medical abortions, and contraceptive devices. I served as the lead biostatistician and helped designing the trial and successfully analyzed the data.
    a. Horwitz G, Roncari D, Braaten KP, Maurer R, Fortin J, Goldberg AB. Moderate intravenous sedation for first trimester surgical abortion: a comparison of adverse outcomes between obese and normal-weight women. Contraception. 2018;97(1):48-53
    b. Janiak E, Freeman S, Maurer R, Berkman LF, Goldberg AB, Bartz D. Relationship of job role and clinic type to perceived stigma and occupational stress among abortion workers. Contraception 2018;98(6):517-521
    c. Roe AH, Fortin J, Janiak E, Maurer R, Goldberg AB. Prevalence and predictors of initiation of intrauterine devices and subdermal implants immediately after surgical abortion. Contraception. 2019 Aug;100(2):89-95.

D. Research Support

Active

5UL1TR002541-02 (Lee M. Nadler, MD) 5/1/18-4/30/23

NIH/NCRR
Harvard Clinical and Translational Science Center
This collaborative and trans-disciplinary environment, with new tools and conceptual approaches will catalyze translation that will result in substantive discoveries impacting the health of our patients and those at risk.
Role: Biostatistician

Family Planning Fellowship Grant (Alisa Goldberg, MD, MPH) 7/1/19-6/30/20

The Family Planning Fellowship grant provides clinical and research training to obstetrician/gynecologists seeking additional subspecialty training in family planning. Fellows are required to complete an original research project during the 2 year program.
Role: Statistician

W81XWH1810667 (Augustine Choi, MD, PhD) 12/1/18-11/30/21
Department of Defense

A Phase II Study of Inhaled Carbon Monoxide for the Treatment of ARDS
The major goal is to evaluate safety and efficacy of inhaled CO (200 ppm) in patients with ARDS.
Role: Statistician

Completed

Department of Defense (Ivan Rosas, MD) 10/1/18–9/30/19

Molecular Profiles of Smokers with Subclinical Interstitial Lung Disease
The goal of this project is to determine the prevalence and long-term progression of subclinical ILD in PLuSS subjects and to define clinical and molecular determinants that predict progression of subclinical ILD in smokers.
Role: Statistician

Congressionally Directed (Elizabeth Henske, MD) 10/1/12-9/30/16
Medical Research Programs

Department of Defense
Targeting Autophagy for the Treatment of TSC and LAM: A phase I trial of Hydroxychlorosquine and Sirolimus
The primary goal of this clinical trial is to establish the safety of sirolimus and hydroxychloroquine in patients
Role: Biostatistician

5P01HL108801-05 (Mark Perrella, MD) 3/1/15-6/30/17

NIH/NHLBI
A Phase I Trial of Inhaled Carbon Monoxide for the Treatment of Sepsis-Induced Acute Respiratory Distress Syndrome (ARDS)
The primary aim of the study is to assess the safety of inhaled carbon monoxide in intubated patients with sepsis-induced ARDS
Role: Biostatistician

5R01HL129920-02 (Ivan Rosas, MD) 10/1/15-6/30/18

NIH/NHLBI
Clinical and Molecular Profile of Smokers with Subclinical Interstitial Lung Disease
The primary aim of the study is to determine prevalence and longitudinal progression of subclinical ILD in smokers enrolled in the Pittsburgh Lung Screening Study.
Role: Biostatistician